Structure Therapeutics Inc.’s GPCR share price has surged by 29.14%, which has investors questioning if this is right time to sell.

Shares of Structure Therapeutics Inc ADR (NASDAQ: GPCR) climbed 6.8% following the news that Pfizer Inc. (NYSE: NYSE:PFE) has discontinued the development of its obesity drug candidate, danuglipron.

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral ...

A new oral weight loss pill shows results similar to Ozempic and Wegovy injections in the treatment of obesity.

Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety ...

Learn how you can lose weight, easier and more effectively than ever. See top suggestions (Ozempic alternatives) that do not require a prescription.

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron. But the biotech has a long way to go to recover after six straight months ...

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...